David Young - 11 Apr 2023 Form 4 Insider Report for Processa Pharmaceuticals, Inc. (PCSA)

Role: President & CEO, Director, 10%+ Owner
Signature: /s/ David Young by Michael B. Kirwan, as Attorney-in-Fact
Issuer symbol: PCSA
Transactions as of: 11 Apr 2023
Transactions value $: $29,000
Form type: 4
Filing time: 13 Apr 2023, 16:51:46 UTC
Previous filing: 10 Feb 2023
Next filing: 14 Apr 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	PCSA	Common Stock	Purchase	$10.4K	+20K	+5.71%	$0.52	370K	11 Apr 2023	Direct	F1
transaction	PCSA	Common Stock	Purchase	$9K	+20K	+5.4%	$0.45	390K	12 Apr 2023	Direct
transaction	PCSA	Common Stock	Purchase	$9.6K	+20K	+5.12%	$0.48	410K	13 Apr 2023	Direct	F2
holding	PCSA	Common Stock						620K	11 Apr 2023	By Young-Plaisance Revocable Trust
holding	PCSA	Common Stock						216K	11 Apr 2023	By Family Entities
holding	PCSA	Common Stock						371K	11 Apr 2023	By CorLyst, LLC

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $0.49 to $0.53, inclusive. The Reporting Person undertakes to provide Processa Pharmaceuticals, Inc. (the "Company"), any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.
F2	The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $0.44 to $0.51, inclusive. The Reporting Person undertakes to provide Processa Pharmaceuticals, Inc. (the "Company"), any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.

Content

The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $0.49 to $0.53, inclusive. The Reporting Person undertakes to provide Processa Pharmaceuticals, Inc. (the "Company"), any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.

The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $0.44 to $0.51, inclusive. The Reporting Person undertakes to provide Processa Pharmaceuticals, Inc. (the "Company"), any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.